Cannabinoids and Alzheimer’s Disease• Investigators at Berlin Germany’s Charite Universitatmedizin, Department of Psychiatry andPsychotherapy, reported that the daily administration of 2.5 mg of synthetic THC over a two-week periodreduced nocturnal motor activity and agitation in AD patients in an open-label pilot studyWalther et al. 2006. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Physcopharmacology 185: 524-528.• Additional cannabinoids were also found to reduce the inflammation associated with Alzheimersdisease in human brain tissue in culture. "Our results indicate that … cannabinoids succeed in preventingthe neurodegenerative process occurring in the disease.“Ramirez et al. 2005. Prevention of Alzheimer’s Disease pathology by cannabinoids. The Journal of Neuroscience 25: 1904-1913.• Cannabinoids offer a multi-faceted approach for the treatment of Alzheimers disease by providingneuroprotection and reducing neuroinflammation, whilst simultaneously supporting the brains intrinsicrepair mechanisms by augmenting neurotrophin expression and enhancing neurogenesis. ... Manipulation ofthe cannabinoid pathway offers a pharmacological approach for the treatment of AD that may be efficaciousthan current treatment regimens.“Campbell and Gowran. 2007. Alzheimers disease; taking the edge off with cannabinoids? British Journal of Pharmacology 152: 655-662• Clinical data presented at the 2003 annual meeting of the International Psychogeriatric Associationpreviously reported that the oral administration of up to 10 mg of synthetic THC reduced agitation andstimulated weight gain in late-stage Alzheimer’s patients in an open-label clinical trialBBC News. August 21, 2003. “Cannabis lifts Alzheimer’s appetite.”
Cannabinoids ObesityBy uncovering the cellular interactions of the cannabinoid Δ 9-tetrahydrocannabinol (Δ9-THC)— major active thecomponent of marijuana— researchers have identified new molecular pathways for treating cardiometabolicdisease. Studies have demonstrated that modulation of the endocannabinoid system holds great therapeutic promisefor the treatment of obesity, dyslipidemia, insulin resistance and atherosclerosis.• Steffens S et al. (2005) Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.Nature 434: 782-786• Van Gaal LF et al. (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-yearexperience from the RIO-Europe study. Lancet 365: 1389-1397 (Note: Persons 15 or older) Prevalence of overweight (BMI 25 to <30) and obesity (BMI 30 or over), 2002
Cannabinoids and DiabetesPreclinical studies indicating that Cannabinoids may modify the disease’s progression and providesymptomatic relief to those suffering from it• Croxford and Yamamura. 2005. Cannabinoids and the immune system: Potential for the treatment of inflammatory diseases. Journal ofNeuroimmunology 166: 3-18.• Lu et al. 2006. The cannabinergic system as a target for anti-inflammatory therapies. Current Topics in Medicinal Chemistry 13: 1401-1426.A 2001 trial demonstrated that delta-9-THC could moderate an animal model of the disease byreducing artificially-elevated glucose levels and insulitis in mice compared to non-treated controls.• Li et al. 2001. Examination of the immunosuppressive effect of delta-9-tetrahydrocannabinol in streptozotocin-induced autoimmunediabetes. International Immunopharmacology (Italy) 4: 699-712.Rats treated with CBD for periods of one to four weeks experienced significant protection fromdiabetic retinopathy. This condition, which is characterized by retinal oxygen deprivation and abreakdown of the blood-retinal barrier, is the leading cause of blindness in working-age adults.• El-Remessy et al. 2006. Neuroprotective and blood-retinal barrier preserving effects of cannabidiol in experimental diabetes. American Journal ofPathology 168: 235-244.
Health Needs of Consumers Research Areas: •Nutrition & Health •Food Science •Interactions between food & consumer •Bio-analysis